ECTRIMS 2023 | The prognostic role of NfL in predicting MS progression

Ahmed Abdelhak, MD, University of California, San Francisco, CA, delves into the significance of neurofilament light (NfL) values gathered from two large, deeply phenotypic cohorts. Boasting over 13,000 visits with NfL data, the research sought temporal associations between NfL elevations and subsequent disease progression. Intriguingly, NfL spikes were identified about a year prior to diagnosing progression linked with a relapse, and between 1-2 years before progression not tied to clinical relapses. This temporal insight underscores the imperative to consider the timeframe of central nervous system damage when designing clinical trials or evaluating therapeutic efficacy. The findings emphasize that progression-related CNS damage likely precedes visible progression by 1-2 years, impacting both clinical trials’ design and patient management. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.